Ibrutinib Linked With Favorable Survival, High Response Rate in CLL

Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate among patients with chronic lymphocytic leukemia (CLL), regardless of prior lines of therapy, according to a study presented at the 2016 Society of Hematologic Oncology annual meeting in Houston, Texas.¹

Researchers conducted a secondary analysis of 2 phase 3 randomized trials observing treatment-naive and previously treated patients who were given ibrutinib. Outcomes were evaluated based on prior lines of therapy and followed discontinuation among these patients.

In total, 271 patients were included, with a median age of 73 years for treatment-naive patients and 66 years for previously treated patients. Among patients who received ibrutinib first or second line, 89% to 92% were progression-free at 2 years.

It was also found that overall response rate was high across all prior lines of therapy, with 91 to 100% among patients treated with ibrutinib first or second line, and 88 to 93% among those treated with ibrutinib as a later line of therapy.

Most observed patients continued use of ibrutinib, with discontinuation less likely among patients treated with ibrutinib in an earlier line of therapy. Median overall survival upon discontinuation of ibrutinib was not reached for those treated in first or second line, in contrast with 7 to 9 months among those treated in later lines of therapy.

Reference

1. Reddy N, O’Brien S, Byrd J, et al. Outcomes with ibrutinib by line of therapy in patients with CLL: analyses from phase 3 data. Paper presented at: 2016 Society of Hematologic Oncology Annual Meeting; September 7-10, 2016; Houston, Texas.